Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma
01 juin 2015 09h00 HE
|
Chinook Therapeutics, Inc.
BERKELEY, Calif., June 1, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO) today announced the presentation of interim safety and efficacy data from an ongoing Phase 1b clinical trial of its...